Effect of kidney transplantation on bone mass and body composition in males.
BACKGROUND
Bone loss is a frequent and well-known complication in the first months after renal transplantation, but there are no data considering body composition variables (bone, fat, and lean mass) together in transplant recipients. This prospective study investigated total body bone density, fat mass, and lean mass before and 1, 2, 3, 4, and 6 months after renal transplantation in male patients who underwent hemodialysis.


METHODS
Twenty consecutive renal transplant male patients aged 23-64 years (mean, 40 years; median, 41 years) received one of two immunosuppressive therapies (cyclosporine+methylprednisolone, or cyclosporine+methylprednisolone+azathioprine). The bone, fat, and lean mass of the total body and its related subregions were assessed by means of dual X-ray photon absorptiometry. Mixed factorial analysis of variance for repeated measurements was used for the statistical analysis.


RESULTS
During the 6 months after transplantation, there was a reduction in trabecular bone mass in the spine, ribs, and pelvis total body subregions; the reduction was statistically significant in the last two subregions. There was no statistically significant difference in the lean mass of the total body or its subregions over time, but there was a statistically significant increase in the fat mass of the total body and all of its subregions; the increase in total and trunk fat mass seemed to be greater in the patients not receiving azathioprine.


CONCLUSIONS
Up to 6 months after renal transplantation in male patients who underwent hemodialysis, there is a marked increase in fat mass, a significant loss of trabecular bone mass, and no change in cortical bone and lean mass.
Ulivieri
Fabio M
FM
Servizio di Medicina Nucleare, Ospedale Maggiore di Milano, via F.Sforza 35, 20122 Milan, Italy. Ulivieri@polic.cilea.it
Piodi
Luca P
LP
Aroldi
Adriana
A
Cesana
Bruno M
BM
D000273:Adipose Tissue / Q000033:anatomy & histology; D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D001379:Azathioprine / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001823:Body Composition / Q000502:physiology*; D015519:Bone Density / Q000502:physiology*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D013997:Time Factors
D015415:Biomarkers; D016572:Cyclosporine; D000469:Alkaline Phosphatase; D001379:Azathioprine; D008775:Methylprednisolone